Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors predictive of adverse drug events and drug-related falls in aged care residents: secondary analysis from the ReMInDAR trial.
Dorj G, Nair NP, Bereznicki L, Kelly TL, Pratt N, Kalisch-Ellett L, Andrade A, Rowett D, Whitehouse J, Widagdo I, Bilton RL, Lim R, Roughead E. Dorj G, et al. Among authors: whitehouse j. Drugs Aging. 2023 Jan;40(1):49-58. doi: 10.1007/s40266-022-00983-6. Epub 2022 Nov 23. Drugs Aging. 2023. PMID: 36422825 Free PMC article. Clinical Trial.
Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcome.
Lim R, Bereznicki L, Corlis M, Kalisch Ellett LM, Kang AC, Merlin T, Parfitt G, Pratt NL, Rowett D, Torode S, Whitehouse J, Andrade AQ, Bilton R, Cousins J, Kelly L, Schubert C, Williams M, Roughead EE. Lim R, et al. Among authors: whitehouse j. BMJ Open. 2020 Apr 22;10(4):e032851. doi: 10.1136/bmjopen-2019-032851. BMJ Open. 2020. PMID: 32327474 Free PMC article.
Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the ReMInDAR trial).
Roughead EE, Pratt NL, Parfitt G, Rowett D, Kalisch-Ellett LM, Bereznicki L, Merlin T, Corlis M, Kang AC, Whitehouse J, Bilton R, Schubert C, Torode S, Kelly TL, Andrade AQ, Post D, Dorj G, Cousins J, Williams M, Lim R. Roughead EE, et al. Among authors: whitehouse j. Age Ageing. 2022 Apr 1;51(4):afac092. doi: 10.1093/ageing/afac092. Age Ageing. 2022. PMID: 35460410 Free PMC article. Clinical Trial.
Correction to: Risk factors predictive of adverse drug events and drug-related falls in aged care residents: secondary analysis from the ReMInDAR trial.
Dorj G, Nair NP, Bereznicki L, Kelly TL, Pratt N, Kalisch-Ellett L, Andrade A, Rowett D, Whitehouse J, Widagdo I, Bilton RL, Lim R, Roughead E. Dorj G, et al. Among authors: whitehouse j. Drugs Aging. 2023 Jan;40(1):89. doi: 10.1007/s40266-022-00996-1. Drugs Aging. 2023. PMID: 36536261 Free PMC article. No abstract available.
Prevalence and Preventability of Adverse Medicine Events in a Sample of Australian Aged-Care Residents: A Secondary Analysis of Data from the ReMInDAR Trial.
Kalisch Ellett LM, Dorj G, Andrade AQ, Bilton RL, Rowett D, Whitehouse J, Lim R, Pratt NL, Kelly TL, Parameswaran Nair N, Bereznicki L, Widagdo I, Roughead EE. Kalisch Ellett LM, et al. Among authors: whitehouse j. Drug Saf. 2023 May;46(5):493-500. doi: 10.1007/s40264-023-01299-z. Epub 2023 Apr 19. Drug Saf. 2023. PMID: 37076609 Free PMC article.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00548-8. doi: 10.1016/S0140-6736(24)00548-8. Online ahead of print. Lancet. 2024. PMID: 38763154 Free article.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00549-X. doi: 10.1016/S0140-6736(24)00549-X. Online ahead of print. Lancet. 2024. PMID: 38763153 Free article.
267 results